Global Acromesomelic Dysplasia Market, By Type (Type I, Type II, type III, Type IV, Type V, Others), Related Disorders (Achondroplasia, Acrodysostosis, Acromicric Dysplasia, Others), Diagnosis (Advanced Imaging Techniques, Specialized X-Ray Studies, Others), Treatment (Symptomatic, Supportive, Others), End Users (Hospitals, Specialty Clinics Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, online Pharmacies and Others) – Industry Trends and Forecast to 2030.
Acromesomelic Dysplasia Market Analysis and Size
Infants suffering from acromesomelic dysplasia frequently have a normal birth weight. Acromelia and mesomelia typically characterize the disorder. These genetic diseases are determined majorly by the combination of genes for a certain trait on the chromosomes received from the father and the mother. The wide commercialization of novel drugs and the existence of pipeline products are the primary factors expected to boost the market growth.
Data Bridge Market Research analyses that the acromesomelic dysplasia market is expected to reach USD 4.43 billion by 2030, which is USD 3 billion in 2022, and is expected to undergo a CAGR of 5% during the forecast period 2023 to 2030. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Acromesomelic Dysplasia Market Scope and Segmentation
2023 to 2030
2021 (Customizable to 2015 - 2020)
Revenue in USD Billion, Volumes in Units, Pricing in USD
Type (Type I, Type II, type III, Type IV, Type V, Others), Related Disorders (Achondroplasia, Acrodysostosis, Acromicric Dysplasia, Others), Diagnosis (Advanced Imaging Techniques, Specialized X-Ray Studies, Others), Treatment (Symptomatic, Supportive, Others), End Users (Hospitals, Specialty Clinics Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, online Pharmacies and Others)
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
Market Players Covered
Zimmer Biomet (U.S.), Johnson and Johnson Services, Inc. (U.S.), Stryker (U.S.), Smith and Nephew plc (U.K.), B. Braun SE (Germany), Corin (U.K.), Waldemer Link GmbH & Co. K.G. (Germany), Wright Medical Group N.V. (U.S.), Arthrex, Inc. (U.S.), Conformis (U.S.), Pfizer Inc. (U.S.), Boston Scientific Corporation (U.S.), GSK plc (U.K.), Lilly (U.S.), Abbott (U.S.), Siemens Healthcare GmbH (Germany), Medacta International (Switzerland), Tecomet,Inc. (U.S.), Peter Brehm GmbH (Germany), MicroPort Scientific Corporation (China), athenahealth, Inc. (U.S.)
Acromesomelic Dysplasia is a kind of highly rare, inherited, progressive skeletal disorder, that results in a certain form of short stature named as short-limb dwarfism. The short stature results from abnormal shortening of the bones in the hands and feet named as acromelia and short forearms and forelegs called mesomelia. The autosomal recessive defect is associated with the Natriuretic Peptide Receptor 2 (NPR2) gene on chromosome 9p13-q12.
Acromesomelic Dysplasia Market Dynamics
- Wide Availability of Advanced Treatment Procedures
With every passing decade, diverse treatment methods are becoming accessible that would help the patients' faster recovery. Abnormal curvature of the spine may be successfully treated with a combination of exercises and physical therapy, other supportive techniques, casts, braces, or in extreme cases, corrective surgery is performed. Physical therapy, other supportive techniques, and/or orthopedic surgery may support to correct certain detailed findings related to acromesomelic dysplasia.
- Increased Demands of Diagnostic Tests
Acromesomelic dysplasia patients emphasize radiographic findings as an important criterion for further treatment through detailed patient history, clinical evaluation, identification of characteristic findings, and several advanced imaging techniques. Specialized x-ray studies may help identify the abnormal development and premature fusion of the regions where the shafts of certain long bones meet their growing ends.
- Increasing Prevalence of Acromesomelic Dysplasia
This rare syndrome's rising prevalence is creating more market growth opportunities. As per National Organization for Rare Disorders in 2005, around ten affected individuals of Hunter-Thompson type ADM, and in medical literature, almost 40 to 50 patients of Maroteaux type AMD were witnessed. The number of Grebe type ADM cases is unknown, but type is believed to be entirely restricted to people living in Brazil. Therefore, the growing incidence demands more treatment procedures, creating opportunities for its growth.
- Lack of skilled professionals
The lack of qualified personnel unable to perform these treatments could curb the growth of the acromesomelic dysplasia market over a forecast period.
- Unavailability of Appropriate Treatments
To treat conditions that are rare, many a times, all treatments are not available, especially in the under-developed countries. The severe patients need to be treated with advanced techniques, but these are sometimes unavailable in the hospitals and clinics. Thus, it hampers the market growth.
This acromesomelic dysplasia market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the acromesomelic dysplasia market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
COVID-19 Impact on Global Acromesomelic Dysplasia Market
COVID-19 has a major global public health crisis on the acromesomelic dysplasia market. During the pandemic, the healthcare facilities and professionals primarily focused on the COVID-19 patients. Several hospitals have decided to cancel or postpone other procedures. In the post pandemic era, the situation improved a bit and physicians and doctors could focus on the other syndromes that include these rare syndromes as well. Thus, COVID-19 left a major impact on the acromesomelic dysplasia market.
Global Acromesomelic Dysplasia Market Scope
The acromesomelic dysplasia market is segmented on the basis of type, related diosrders, diagnosis, treatment, distribution channel and end-user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
- Type I
- Type II
- type III
- Type IV
- Type V
- Acromicric Dysplasia
- Advanced Imaging Techniques
- Specialized X-Ray Studies
- Specialty Clinic
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacies
Acromesomelic Dysplasia Market Regional Analysis/Insights
The acromesomelic dysplasia market is analyzed and market size insights and trends are provided by type, related diosrders, diagnosis, treatment, distribution channel and end-user as referenced above.
The major countries covered in the acromesomelic dysplasia market report are the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
North America is dominating the market in the forecast period because of the high healthcare expenditure and R&D. It has been witnessed that Europe accounts for the second-largest market share because of the increased refined healthcare facilities.
Asia-Pacific is considered to have the most lucrative period because of the increased advancement in technology and increasing healthcare expenditure and growing awareness programs.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Competitive Landscape and Global Acromesomelic Dysplasia Market Share Analysis
The acromesomelic dysplasia market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to acromesomelic dysplasia market.
Key players operating in the acromesomelic dysplasia market include:
- Zimmer Biomet (U.S.)
- Johnson and Johnson Services, Inc. (U.S.)
- Stryker (U.S.)
- Smith and Nephew plc (U.K.)
- B. Braun SE (Germany)
- Corin (U.K.)
- Waldemer Link GmbH & Co. KG (Germany)
- Wright Medical Group N.V. (U.S.)
- Arthrex, Inc. (U.S.)
- Conformis (U.S.)
- Pfizer Inc. (U.S.)
- Boston Scientific Corporation (U.S.)
- GSK plc (U.K.)
- Lilly (U.S.)
- Abbott (U.S.)
- Siemens Healthcare GmbH (Germany)
- Medacta International (Switzerland)
- Tecomet,Inc. (U.S.)
- Peter Brehm GmbH (Germany)
- MicroPort Scientific Corporation (China)
- athenahealth, Inc. (U.S.)